ADC Therapeutics Analyst Ratings
Buy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth Outlook
ADC Therapeutics Analyst Ratings
ADC Therapeutics Analyst Ratings
Buy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progress
Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)
ADC Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), TFF Pharmaceuticals (TFFP)
ADC Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
Jefferies Cuts ADC Therapeutics Stock Target to $13, Maintains Buy
Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT) and Cresco Labs (OtherCRLBF)
ADC Therapeutics Analyst Ratings
ADC Therapeutics Analyst Ratings
RBC Lifts Price Target on ADC Therapeutics to $8 From $6, 'Encouraged' by Competitive Positioning; Outperform, Speculative Risk Kept
RBC Capital Remains a Buy on ADC Therapeutics (ADCT)
ADC Therapeutics Analyst Ratings
Buy Rating Affirmed for ADC Therapeutics With Raised Price Target Amid Promising Clinical Trials and Strong Balance Sheet
RBC Capital Keeps Their Buy Rating on ADC Therapeutics (ADCT)
Optimistic Outlook: Buy Rating for ADC Therapeutics Amid Anticipated Clinical Milestones and Strong Financials